HARBIN, China, July 3, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that the Company's Siberian Ginseng Extract was recognized as Safe Medicine at the 8th session of the Selection Event, hosted by the Health Newspaper in China and supported by the Ministry of Health of China.
In May 2012, at the 8th session of the Selection event, a total of 30 medicines manufactured by 30 Chinese pharmaceutical companies were recognized as Safe Medicine by civilians. Since its debut in 2004, the Selection Event is well known in China's pharmaceutical industry. The selection procedure includes conducting surveys of Chinese consumers and their opinion of products offered by domestic pharmaceutical companies The Selection Event is designed to understand the needs of patients and gain valuable insights from the general population on the quality and remedial effect of different medications.
"We are honored that our Siberian Ginseng Extract product has been recognized as Safe Medicine by our domestic consumers along with 29 other medicines from well-known pharmaceutical companies. We believe this reflects on our commitment to deliver high-quality products which optimally meet our customer's needs," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are encouraged by this recognition as we continue to make efforts to expand the scope and reach of Siberian Ginseng in China and internationally."
For more information on the 8th session of the Selection Event, please visit http://aqyy.jkb.com.cn.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
SOURCE China Botanic Pharmaceutical Inc.